Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.

作者: Erin E. Bonar , Lisham Ashrafioun , Mark A. Ilgen

DOI: 10.1016/J.DRUGALCDEP.2014.07.009

关键词:

摘要: BACKGROUND: The abuse of synthetic cannabinoids has emerged as a public health concern over the past few years, yet little data exist characterizing use cannabinoids, particularly among patients seeking substance disorder (SUD) treatment. In sample entering residential SUD treatment, we examined prevalence and motivations for cannabinoid use, relationships with other demographic characteristics. METHODS: Patients (N=396; 67% male, 75% White, Mage=34.8) completed self-report screening surveys about lifetime route administration, motives use. RESULTS: A total 150 (38%) reported using in their lifetimes, primarily by smoking (91%). Participants chose multiple most commonly endorsed included curiosity (91%), feeling good/getting high (89%), relaxation (71%), getting without having positive drug test (71%). Demographically, those who used were younger more White. They had higher rates scores on measures depression psychiatric distress. CONCLUSIONS: Lifetime was relatively common many it doing so because they believed would not result test. Further research is needed to characterize extent treatment samples, establish understanding longitudinal trajectories combination distress, outcomes. Language: en

参考文章(19)
Monica J. Barratt, Vince Cakic, Simon Lenton, Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review. ,vol. 32, pp. 141- 146 ,(2013) , 10.1111/J.1465-3362.2012.00519.X
A THOMAS McLELLAN, LESTER LUBORSKY, GEORGE E. WOODY, CHARLES P. O??BRIEN, An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. Journal of Nervous and Mental Disease. ,vol. 168, pp. 26- 33 ,(1980) , 10.1097/00005053-198001000-00006
Ryan Vandrey, Kelly E. Dunn, Jeannie A. Fry, Elizabeth R. Girling, A survey study to characterize use of Spice products (synthetic cannabinoids) Drug and Alcohol Dependence. ,vol. 120, pp. 238- 241 ,(2012) , 10.1016/J.DRUGALCDEP.2011.07.011
William E. Fantegrossi, Jeffery H. Moran, Anna Radominska-Pandya, Paul L. Prather, Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? Life Sciences. ,vol. 97, pp. 45- 54 ,(2014) , 10.1016/J.LFS.2013.09.017
Jennifer A. McLaren, Edmund Silins, Delyse Hutchinson, Richard P. Mattick, Wayne Hall, Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. International Journal of Drug Policy. ,vol. 21, pp. 10- 19 ,(2010) , 10.1016/J.DRUGPO.2009.09.001
Adam R. Winstock, Monica J. Barratt, Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample Drug and Alcohol Dependence. ,vol. 131, pp. 106- 111 ,(2013) , 10.1016/J.DRUGALCDEP.2012.12.011
MB Forrester, K Kleinschmidt, E Schwarz, A Young, Synthetic cannabinoid and marijuana exposures reported to poison centers. Human & Experimental Toxicology. ,vol. 31, pp. 1006- 1011 ,(2012) , 10.1177/0960327111421945
Lloyd D. Johnston, Patrick M. O’Malley, Jerald G. Bachman, Monitoring the Future: National Results on Adolescent Drug Use: Overview of Key Findings FOCUS. ,vol. 1, pp. 213- 234 ,(2003) , 10.1176/FOC.1.2.213